Volume 97, Issue 4
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645



Acute and chronic infection with affects millions of people. The current therapeutic options are highly toxic and often not effective. Liposomal amphotericin B (LAMB) has been demonstrated previously to have some activity in murine models. In our studies, higher dosages given multiple times were tested for activity against acute or chronic disease, exploring whether intermittent and brief regimens could be effective, as might then prove useful in human, particularly outpatient, therapy. For acute infection, LAMB 25 mg/kg intravenously (i.v.) given one to three times prolonged survival and caused a rapid disappearance of Y strain trypomastigotes from the blood. However, even four or six doses of LAMB 30 mg/kg i.v., did not result in the cure of Y strain infection, with all mice relapsing after being immunosuppressed with cyclophosphamide. Similarly, chronic infection due to the CL strain was found to be unaltered by 1–3 treatments with LAMB 25 mg/kg. All surviving mice had histopathological evidence of infection in one or more tissues and equivalent antibody titers regardless of treatment regimen. Overall, LAMB at doses up to 30 mg/kg i.v. prolonged survival, but these doses were not curative in the regimens studied.


Article metrics loading...

The graphs shown below represent data from March 2017
Loading full text...

Full text loading...



  1. Bern C, Kjos S, Yabsley MJ, Montgomery SP, , 2011. Trypanosoma cruzi and Chagas’ disease in the United States. Clin Microbiol Rev 24: 655681.[Crossref] [Google Scholar]
  2. Bern C, Montgomery SP, , 2009. An estimate of the burden of Chagas disease in the United States. Clin Infect Dis 49: e52e54.[Crossref] [Google Scholar]
  3. Jurberg C, , 2009. Chagas: one hundred years later. Bull World Health Organ 87: 491492.[Crossref] [Google Scholar]
  4. Kirchhoff LV, , 2011. Epidemiology of American trypanosomiasis (Chagas disease). Adv Parasitol 75: 118.[Crossref] [Google Scholar]
  5. Tanowitz HB, Kirchhoff LV, Simon D, Morris SA, Weiss LM, Wittner M, , 1992. Chagas’ disease. Clin Microbiol Rev 5: 400419.[Crossref] [Google Scholar]
  6. World Health Organization, 2015. Chagas disease in Latin America: an epidemiological update based on 2010 estimates. Wkly Epidemiol Rec 90: 3344. [Google Scholar]
  7. Coura JR, Vinas PA, , 2010. Chagas disease: a new worldwide challenge. Nature 465: S6S7.[Crossref] [Google Scholar]
  8. Brown EL, Roellig DM, Gompper ME, Monello RJ, Wenning KM, Gabriel MW, Yabsley MJ, , 2010. Seroprevalence of Trypanosoma cruzi among eleven potential reservoir species from six states across the southern United States. Vector Borne Zoonotic Dis 10: 757763.[Crossref] [Google Scholar]
  9. Urbina JA, , 2010. Specific chemotherapy of Chagas disease: relevance, current limitations and new approaches. Acta Trop 115: 5568.[Crossref] [Google Scholar]
  10. Buckner FS, Navabi N, , 2010. Advances in Chagas disease drug development: 2009–2010. Curr Opin Infect Dis 23: 609616.[Crossref] [Google Scholar]
  11. Coura JR, Borges-Pereira J, , 2012. Chagas disease: what is known and what should be improved: a systemic review. Rev Soc Bras Med Trop 45: 286296.[Crossref] [Google Scholar]
  12. Lescure FX, Le Loup G, Freilij H, Develoux M, Paris L, Brutus L, Pialoux G, , 2010. Chagas disease: changes in knowledge and management. Lancet Infect Dis 10: 556570.[Crossref] [Google Scholar]
  13. Molina I, ., 2014. Randomized trial of posaconazole and benznidazole for chronic Chagas’ disease. N Engl J Med 370: 18991908.[Crossref] [Google Scholar]
  14. Molina I, Salvador F, Sanchez-Montalva A, , 2015. The use of posaconazole against Chagas disease. Curr Opin Infect Dis 28: 397407.[Crossref] [Google Scholar]
  15. Urbina JA, , 2015. Recent clinical trials for the etiological treatment of chronic Chagas disease: advances, challenges and perspectives. J Eukaryot Microbiol 62: 149156.[Crossref] [Google Scholar]
  16. Morillo CA, STOP-CHAGAS Investigators.; , 2017. Benznidazole and posaconazole in eliminating parasites in asymptomatic T. cruzi carriers: the STOP-CHAGAS Trial. J Am Coll Cardiol 69: 939947.[Crossref] [Google Scholar]
  17. Abitbol H, Boris E, Piulats E, Podesta D, Maranon J, , 1964. Therapeutic action of amphotericin B in acute Chagas’ disease. Bol Chil Parasitol 19: 132134. [Google Scholar]
  18. Cencig S, Coltel N, Truyens C, Carlier Y, , 2011. Parasitic loads in tissues of mice infected with Trypanosoma cruzi and treated with AmBisome. PLoS Negl Trop Dis 5: e1216.[Crossref] [Google Scholar]
  19. Yardley V, Croft SL, , 1999. In vitro and in vivo activity of amphotericin B-lipid formulations against experimental Trypanosoma cruzi infections. Am J Trop Med Hyg 61: 193197.[Crossref] [Google Scholar]
  20. Cordeiro FD, Martins-Filho OA, Da Costa Rocha MO, Adad SJ, Correa-Oliveira R, Romanha AJ, , 2001. Anti-Trypanosoma cruzi immunoglobulin G1 can be a useful tool for diagnosis and prognosis of human Chagas’ disease. Clin Diagn Lab Immunol 8: 112118. [Google Scholar]

Data & Media loading...

  • Received : 12 Dec 2016
  • Accepted : 02 Jul 2017
  • Published online : 14 Aug 2017

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error